Medivir Mulls Separation As Simeprevir Royalties Decline

As royalties from hepatitis C therapy simeprevir continue to decline its originator, Swedish biotech Medivir, is considering a separate public listing for its commercial operations that would allow the remaining concern to return to its previous R&D roots.